Today's Rundown Editor’s Note: FierceBiotech will not publish on Wednesday this week due to the July 4th holiday, but we’ll be back in your inbox on Thursday, July 5. Featured Story | | | Tuesday, July 3, 2018 Novartis has walked away from Aveo Pharmaceuticals’ AV-380 three years after paying $15 million (€13 million) upfront for the asset. The action cuts short a relationship that was starting to sour amid the slow progress of the treatment for severe, cancer-related weight loss. |
|
|
Top Stories Tuesday, July 3, 2018 If you thought we wouldn't be hearing from Martin Shkreli after he was packed off to serve seven years for securities fraud, think again. The pharma bro, infamous for his combative tweets and general "insolent" demeanor, may be blogging biopharma tips—from prison. Tuesday, July 3, 2018 In the aftermath of another industry party that objectified women, the top Democrat on the Senate Health, Education, Labor and Pensions Committee sent letters to BIO and PhRMA about their efforts to combat workplace harassment at their member companies. Tuesday, July 3, 2018 Titan has been cleared to start the second stage in a trial of its ropinirole implant for Parkinson’s—but will have to postpone it because of financial constraints. Tuesday, July 3, 2018 Antibe Therapeutics has posted secondary endpoint data from a phase 2b trial of its alternative to nonsteroidal anti-inflammatory drug naproxen. The data add to evidence that Antibe’s drug, ATB-346, is safer than naproxen, potentially making it a better choice for patients with osteoarthritis, rheumatoid arthritis and other diseases. Enrollment Showcase | | | Sponsored by: Bioinformatics at UTHealth SBMI UTHealth SBMI now offers a M.S. track in clinical and translational bioinformatics. |
|
|
Resources Life Science Strategy Group Take this anonymous 10-minute survey to share your thoughts on leading eClinical technology solutions and earn up to $55 honoraria. Take the survey now! Sponsored by: Blue Latitude Health Blue Latitude Health explores the commercial barriers and new stakeholder connections for pharma companies developing precision medicines, and reveals how to grasp novel opportunities in the new era of healthcare. Presented by: Patheon, part of Thermo Fisher Scientific “Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure. Sponsored by: Seton Hall Law 4-day interactive educational program trusted by multi-national companies as part of their compliance training for employees. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating globally. Visit event homepage for session topics. Sponsored by: Docusign Life science companies are experiencing a significant transformation in how they bring new products to market. | 
